NIH cuts delayed a cancer trial. Patients lost time they didn't have
Federal funding cuts to the NIH have delayed a critical clinical trial for DIPG, a deadly pediatric brain tumor with very few treatment options. The delay is illustrated through the story of 8-year-old John Paul Macri, whose family faced a race against time waiting for the trial to resume. The case highlights the real human cost of research budget reductions.
The Atomic take
DIPG trials are rare precisely because the patient population is small and the disease is fast, so a funding pause of even a few months can outlast a child like John Paul Macri's remaining window to enroll. The real damage here is not just one delayed study but the compounding effect on early-phase pediatric oncology, where researchers depend on continuous NIH support to keep enrollment open and dosing on schedule. Watch whether affected trials restore their timelines and whether Congress or the NIH carves out protections for active pediatric cancer studies caught in broader budget reductions.
Read the full story at CNBC →Know where humanity is headed.
Five forces, one investment thesis a day. Free, every weekday morning.
Get The Atomic Five